Virgilio M, Ramnani B, Chen T, Disbennett W, Lubow J, Welch J
    
    
    Nat Commun. 2024; 15(1):5514.
  
  
    PMID: 38951492
    
          PMC: 11217462.
    
          DOI: 10.1038/s41467-024-49635-w.
      
 
                                  
  
    Zhao X, Zhao Y, Du J, Gao P, Zhao K
    
    
    Front Immunol. 2021; 12:732775.
  
  
    PMID: 34566998
    
          PMC: 8459832.
    
          DOI: 10.3389/fimmu.2021.732775.
      
 
                                  
  
    Khan H, Sumner R, Rasaiyaah J, Tan C, Rodriguez-Plata M, van Tulleken C
    
    
    Elife. 2020; 9.
  
  
    PMID: 33300875
    
          PMC: 7759385.
    
          DOI: 10.7554/eLife.60821.
      
 
                                  
  
    Murakami H, Suzuki T, Tsuchiya K, Gatanaga H, Taura M, Kudo E
    
    
    Viruses. 2020; 12(3).
  
  
    PMID: 32210193
    
          PMC: 7150949.
    
          DOI: 10.3390/v12030355.
      
 
                                  
  
    Wang Q, Su L
    
    
    mBio. 2019; 10(4).
  
  
    PMID: 31431548
    
          PMC: 6703422.
    
          DOI: 10.1128/mBio.01344-19.
      
 
                              
              
                              
                                      
  Regulation of CD4 Receptor and HIV-1 Entry by MicroRNAs-221 and -222 during Differentiation of THP-1 Cells.
  
    Lodge R, Gilmore J, Barbosa J, Lombard-Vadnais F, Cohen E
    
    
    Viruses. 2018; 10(1).
  
  
    PMID: 29301198
    
          PMC: 5795426.
    
          DOI: 10.3390/v10010013.
      
 
                                          
                                                          
  Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells.
  
    Miller C, Akiyama H, Agosto L, Emery A, Ettinger C, Swanstrom R
    
    
    J Virol. 2017; 91(13).
  
  
    PMID: 28424288
    
          PMC: 5469257.
    
          DOI: 10.1128/JVI.00051-17.
      
 
                                          
                                                          
  The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention.
  
    Gonzalez M
    
    
    Int J Mol Sci. 2017; 18(1).
  
  
    PMID: 28075409
    
          PMC: 5297760.
    
          DOI: 10.3390/ijms18010126.
      
 
                                          
                                                          
  HIV-1 Vpr degrades the HLTF DNA translocase in T cells and macrophages.
  
    Lahouassa H, Blondot M, Chauveau L, Chougui G, Morel M, Leduc M
    
    
    Proc Natl Acad Sci U S A. 2016; 113(19):5311-6.
  
  
    PMID: 27114546
    
          PMC: 4868422.
    
          DOI: 10.1073/pnas.1600485113.
      
 
                                          
                                                          
  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.
  
    Roesch F, Richard L, Rua R, Porrot F, Casartelli N, Schwartz O
    
    
    J Virol. 2015; 89(23):12118-30.
  
  
    PMID: 26401039
    
          PMC: 4645299.
    
          DOI: 10.1128/JVI.02098-15.
      
 
                                          
                                                          
  HIV-1 Vpr induces interferon-stimulated genes in human monocyte-derived macrophages.
  
    Zahoor M, Xue G, Sato H, Murakami T, Takeshima S, Aida Y
    
    
    PLoS One. 2014; 9(8):e106418.
  
  
    PMID: 25170834
    
          PMC: 4149569.
    
          DOI: 10.1371/journal.pone.0106418.
      
 
                                          
                                                          
  Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells.
  
    de Silva S, Planelles V, Wu L
    
    
    PLoS One. 2012; 7(5):e35385.
  
  
    PMID: 22570689
    
          PMC: 3343049.
    
          DOI: 10.1371/journal.pone.0035385.
      
 
                                          
                                                          
  The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase.
  
    Casey L, Wen X, de Noronha C
    
    
    Cytokine. 2010; 51(1):1-9.
  
  
    PMID: 20347598
    
          PMC: 2880205.
    
          DOI: 10.1016/j.cyto.2010.02.018.
      
 
                                          
                                                          
  Anti-Vpr activity of a yeast chaperone protein.
  
    Benko Z, Liang D, Agbottah E, Hou J, Chiu K, Yu M
    
    
    J Virol. 2004; 78(20):11016-29.
  
  
    PMID: 15452222
    
          PMC: 521794.
    
          DOI: 10.1128/JVI.78.20.11016-11029.2004.
      
 
                                          
                                                          
  Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators.
  
    Kino T, Gragerov A, Slobodskaya O, Tsopanomichalou M, Chrousos G, Pavlakis G
    
    
    J Virol. 2002; 76(19):9724-34.
  
  
    PMID: 12208951
    
          PMC: 136530.
    
          DOI: 10.1128/jvi.76.19.9724-9734.2002.
      
 
                                          
                                                          
  HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells.
  
    Eckstein D, Sherman M, Penn M, Chin P, De Noronha C, Greene W
    
    
    J Exp Med. 2001; 194(10):1407-19.
  
  
    PMID: 11714748
    
          PMC: 2193684.
    
          DOI: 10.1084/jem.194.10.1407.
      
 
                                          
                                                          
  Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity.
  
    Watanabe T, Watanabe S, Ito H, Kida H, Kawaoka Y
    
    
    J Virol. 2001; 75(12):5656-62.
  
  
    PMID: 11356973
    
          PMC: 114278.
    
          DOI: 10.1128/JVI.75.12.5656-5662.2001.
      
 
                                          
                                                          
  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.
  
    Ikuta K, Suzuki S, Horikoshi H, Mukai T, Luftig R
    
    
    Microbiol Mol Biol Rev. 2000; 64(4):725-45.
  
  
    PMID: 11104817
    
          PMC: 99012.
    
          DOI: 10.1128/MMBR.64.4.725-745.2000.
      
 
                                          
                                                          
  Impairment of human immunodeficiency virus type 1 (HIV-1) entry into Jurkat T cells by constitutive expression of the HIV-1 vpr protein: role of CD4 down-modulation.
  
    Conti L, Varano B, Gauzzi M, Matarrese P, Federico M, Malorni W
    
    
    J Virol. 2000; 74(21):10207-11.
  
  
    PMID: 11024150
    
          PMC: 102060.
    
          DOI: 10.1128/jvi.74.21.10207-10211.2000.
      
 
                                          
                                                          
  Maintenance of an intact human immunodeficiency virus type 1 vpr gene following mother-to-infant transmission.
  
    Yedavalli V, Chappey C, Ahmad N
    
    
    J Virol. 1998; 72(8):6937-43.
  
  
    PMID: 9658150
    
          PMC: 109910.
    
          DOI: 10.1128/JVI.72.8.6937-6943.1998.